Willow
Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) today announced its
receipt of conditional approval from the Toronto Stock Exchange (the “TSX”) to
list its common shares on the TSX. According to the update, final approval of
the listing is subject to Willow Biosciences meeting certain TSX customary
conditions, and Willow will issue a statement upon TSX’s confirmation of the
commencement date. “Listing on the TSX is a significant milestone for Willow.
The TSX will broaden our investment appeal and leave us well positioned to
execute on our strategic initiatives for 2020 and beyond,” Willow President and
Chief Executive Officer Trevor Peters said in the news release. “We are excited
to add this to our 2019 accomplishments for Willow, which has seen us complete
a go-public transaction, raise $37 million in a private placement and
subsequent warrant exercise, enter into a potentially game-changing strategic
partnership with Noramco, Inc., build out three state-of-the-art laboratories
and continue to advance our cannabidiol producing yeast strain towards scale-up
expected in the first half of 2020. Willow is uniquely positioned as one of the
few public pure-play synthetic biology companies in the world targeting the
potentially massive consumer packaged goods and pharmaceutical industries, and
being listed on the TSX helps to increase our exposure to global investors.”
To view the full press release, visit http://ibn.fm/z4R99
About Willow Biosciences Inc.
Willow is a Canadian biotechnology company based in Calgary,
Alberta, that produces high purity, plant-derived compounds that provide
building blocks for the global pharmaceutical, health and wellness, and
consumer packaged goods industries. Willow’s current focus is in the production
of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders,
among other significant indications. Willow’s science team has a proven track
record of developing manufacturing technologies for high purity compounds in
pain and cancer treatments. Willow’s manufacturing process creates a
consistent, scalable and sustainable product that allows for the discovery and
development of new life changing drugs. For more information, visit the
company’s website at www.WillowBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment